Strong FY25 growth tempered by the Q4 miss
26/02/26 -"Novonesis stumbled at the finish line — Q4 25 revenue and EBITDA missed consensus by 2.3% and 2.9% respectively, dragged down by weakness in the Planetary Health division. Margins held up well, with ..."
Pages
51
Language
English
Published on
26/02/26
You may also be interested by these reports :
27/02/26
The Q4 results were ahead of consensus, but a lack of 2026 sales guidance casts doubt over Grifols’ ability to deliver on its 2029 sales and ...
27/02/26
The Q4 sales exceeded expectations, though ‘adjusted’ EBITDA was somewhat behind the consensus. The Q4 performance was driven by LatAm, Animal ...
26/02/26
Even though the H2 25 results were ahead of consensus, the 2026 outlook was below the street’s expectations. While Branded posted strong H2 growth, ...
26/02/26
Novonesis stumbled at the finish line — Q4 25 revenue and EBITDA missed consensus by 2.3% and 2.9% respectively, dragged down by weakness in the ...